FDA Clears Motivista as First Digital Treatment for Negative Symptoms of Schizophrenia

Click Therapeutics announced this week that its smartphone application, Motivista, is the first treatment authorized by the Food and Drug Administration specifically for the negative symptoms of schizophrenia. But the clinical evidence behind the clearance is narrower than the milestone suggests. While the application outperformed a control program on a clinician-rated scale, patients' own ratings of their improvement showed no significant difference by the end of the trial.[3][6]

The FDA cleared Motivista on July 30 as a Class II medical device through its 510(k) pathway, a regulatory route for products substantially equivalent to something already on the market. The agency authorized it strictly as an adjunct to standard outpatient care, including antipsychotic medication, for adults whose positive symptoms are clinically stable.[4][6]

Negative symptoms—which include social withdrawal, flattened emotional expression, and a reduced ability to experience or anticipate pleasure—affect the majority of people living with schizophrenia. These manifestations are often the most disabling aspects of the disorder, severely limiting a patient's ability to maintain employment or relationships.[1][3][4]

Traditional antipsychotic medications, which effectively target positive symptoms like hallucinations and delusions, rarely improve these negative deficits. "For decades, patients living with schizophrenia and the clinicians who care for them have had few options for addressing negative symptoms," Click Therapeutics chief executive David Benshoof Klein said in a statement.[1][3]

The lack of pharmacological options for negative symptoms has forced psychiatrists to rely on off-label prescribing or general psychosocial support, often with limited success. Several pharmaceutical candidates designed to tackle these symptoms remain in clinical development, but none have yet cleared the regulatory threshold for a specific indication.[1][3]

The CONVOKE trial results

The clearance rests entirely on the Phase 3 CONVOKE study, published September 25 in JAMA Network Open. Researchers randomized 457 stable outpatients across 66 sites in the United States to use either Motivista or a digital control application for 16 weeks, followed by a four-week safety observation period.[4][6]

The therapeutic application guides users through a structured course of cognitive behavioral therapy and social skills training. The control application, by contrast, delivered short educational lessons designed to be engaging but explicitly devoid of any therapeutic content. Patients actively receiving in-person psychotherapy were excluded from the trial.[1][3][6]

The intervention uses tailored goal setting, cognitive restructuring, and social skills training to address a lack of drive and sociability. By breaking down daily tasks into manageable digital interactions, the software attempts to bypass the motivational deficits that characterize the disorder, prompting patients to engage in behaviors they might otherwise avoid.[1]

On the trial's primary endpoint—the 36-point Clinical Assessment Interview for Negative Symptoms (CAINS-MAP) scale—Motivista users achieved a 6.8-point improvement from baseline. Participants using the control application recorded a 4.2-point improvement, giving the therapeutic app a modest 2.6-point advantage over the digital placebo.[3][4][6]

However, the clinical benefits thinned out beyond that primary clinician-rated measure. Expressive negative symptoms, such as reduced speech and flattened affect, did not differ significantly between the two groups. Positive symptoms also remained unchanged across both cohorts, aligning with the application's targeted design.[6]

Most notably, participants' own global ratings of their improvement favored Motivista at the eight-week mark but no longer showed a statistically significant difference at week 16. The trial also has not yet published data demonstrating whether the reduction in clinician-rated symptoms translated into measurable improvements in daily functioning.[6]

Safety and commercial rollout

The safety profile proved highly favorable, with no serious treatment-related adverse events reported during the study period. Participants in the Motivista arm spent a median of six minutes per day using the application, compared to a median of two minutes per day for the control group.[4]

Despite the negative symptoms of schizophrenia making it inherently difficult for patients to feel motivated, the application maintained high engagement. Data showed that 70.4 percent of Motivista users and 76.5 percent of control users remained active on their respective applications through the fifteenth week of the trial.[4]

The commercial future of the application, however, remains undefined. Click Therapeutics co-developed Motivista over several years with pharmaceutical manufacturer Boehringer Ingelheim. But Boehringer handed back the commercial rights to the prescription therapeutic earlier this year, shortly after the Phase 3 trial results were finalized.[1][3]

Click Therapeutics has not yet disclosed a launch date, a pricing structure, or an insurance coverage strategy for the application. The company stated this week that it is actively working with payers, healthcare providers, and patient advocacy organizations to expand access as it prepares for broader commercial availability.[6]

The broader digital landscape

The regulatory pathway itself places strict boundaries on what the authorization means in practice. Because Motivista was cleared through the 510(k) process rather than approved as a new drug, the FDA determined it was substantially equivalent to an existing digital therapeutic, specifically the depression application Rejoyn.[4]

The agency's summary explicitly notes that Motivista has not been studied for treating the positive symptoms of schizophrenia and is not intended for that use. It remains an adjunctive tool, meaning patients must continue their established pharmacotherapy while using the application to manage their condition.[4][6]

The clearance arrives during a turbulent period for the prescription digital therapeutics industry. While Click Therapeutics previously secured FDA authorization for a smartphone application aimed at preventing migraines, other developers in the space have struggled to convert regulatory clearances into sustainable medical products.[1]

Pear Therapeutics, a high-profile developer of authorized applications for substance use disorders and insomnia, filed for bankruptcy in 2023. The company cited persistent difficulties in securing insurance reimbursement and generating revenue, highlighting the commercial hurdles Motivista will face upon its eventual launch.[1]